Prospective randomised study of the impact of preoperative administration of mitomycin-C by electromotive drug administration (EMDA) in patients with non-muscle invasive urothelial carcinoma

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510867-42-00

Acronym

URO-EMDA-2022-1

Enrollment

228

Registered

2024-10-25

Start date

2023-04-24

Completion date

Unknown

Last updated

2024-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-muscle invasive bladder tumors

Brief summary

Recurrence free survival, Progresion free survival

Detailed description

Total cases of adverse effects by group, Therapeutic completion rate by group, Impact of recurrence free survival and progresion free survival depending on inflammatory response parameters

Interventions

DRUGMITOMYCIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Recurrence free survival, Progresion free survival	—

Secondary

Measure	Time frame
Total cases of adverse effects by group, Therapeutic completion rate by group, Impact of recurrence free survival and progresion free survival depending on inflammatory response parameters	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026